Bayer's Breakthrough: New Drug Offers Relief for Breast Cancer Survivors Battling Hot Flashes
An experimental drug by Bayer, elinzanetant, shows promise in alleviating hot flashes and night sweats in breast cancer survivors undergoing hormone-suppressing therapy. The drug is part of a new class called neurokinin receptor antagonists, which target brain mechanisms causing these symptoms. The study highlights its potential in improving quality of life.
Bayer's new non-hormonal drug, elinzanetant, shows encouraging results in reducing vasomotor symptoms among breast cancer survivors undergoing hormone-suppressing therapy. The findings, published in The New England Journal of Medicine, underline a significant decrease in moderate-to-severe hot flashes for over 70% of participants using the drug.
The trial, involving 474 patients, revealed that elinzanetant not only alleviated hot flashes but also improved sleep and menopausal quality of life within 12 weeks. Dr. Fatima Cardoso emphasized that treating these symptoms is crucial to ensuring adherence to cancer medication, as discomfort often leads patients to discontinue treatment prematurely.
As Bayer awaits regulatory approval from the FDA and EMA, the research reiterates the need for effective management of treatment-related symptoms to enhance survival rates among breast cancer patients.
(With inputs from agencies.)
Google News